Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
RERegeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ Global Select · Currency in USD
$805.02 ▼ -14.07 (-1.72%)
At close: Oct 23, 4:00 PM ET. Market closed.
$804.00 ▼ -1.02 (-0.13%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$819.09
Open
$819.09
Day's Range
$801.22 – $819.09
52 Week Range
$575.93 – $859.34
Volume
527,718
Avg. Volume
790,743
Market Cap
$82.88B
Beta (5Y Monthly)
0.24
PE Ratio (TTM)
19.22
EPS (TTM)
$41.86
Earnings Date
Oct 30, 2026
Forward Dividend & Yield
$3.76 (0.47%)
Ex-Dividend Date
Aug 18, 2026
1y Target Est
$856.80

Profile: Regeneron Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
15,410
CEO
Leonard S. Schleifer

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients.

Earnings

Next report: Fri, Oct 30, 2026
EPS estimate $16.36 · Revenue est. $4.56B
DateEst.Actual
Jul 30, 2026$10.16$14.29Beat
Apr 29, 2026$8.91$9.47Beat
Jan 30, 2026$10.74$11.44Beat
Oct 28, 2025$9.65$11.83Beat
Aug 1, 2025$8.43$12.89Beat
Apr 29, 2025$8.62$8.22Miss

Analyst view

Consensus price target
$856.80 ▲ +6.4%
Range $750.00 – $1,030.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Get free alerts on REGN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.